water N-methyl-2-pyrrolidone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: water N-methyl-2-pyrrolidone
• 英文别名: N-methylpyrrolidone-water；1-methylpyrrolidin-2-one;hydrate
• 化学式: C₅H₉NO*H₂O
• 分子量: 117.148
• InChiKey: HCSCWJCZRCSQFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.59
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  water N-methyl-2-pyrrolidone 、 布洛芬 反应 2.0h， 生成 N-methyl-2-pyrrolidone ibuprofenate
  参考文献：
  名称：

  Ionic liquids with N-methyl-2-pyrrolidonium cation as an enhancer for topical drug delivery: Synthesis, characterization, and skin-penetration evaluation

  摘要：

  The development of non-toxic ionic liquid-based active pharmaceutical ingredients (IL-APIs) for effective topical drug delivery is still challenging. The properties of IL-APIs can be boosted up by selecting potential biocompatible cations. Here, we introduced N-methyl-2-pyrrolidone (NMP) as a potent biocompatible counter ion to prepare ionic liquefied drugs for topical drug delivery. The cytotoxicity of NMP cation was investigated using mammalian cell lines (HepG2, NIH3T3 and L929 cells) and compared with conventional IL-forming cations. The synthesized NMP cation has lower toxicity than that of conventional IL-forming cations. The NMP cation showed at least 3.6, 15.2 and 58.9 times lower toxicity than that of conventional imidazolium, ammonium and phosphonium cations, respectively. The synthesized NMP-based ionic liquid (NMP-IL) was characterized using H-1 & C-13 NMR, FT-IR, DSC and TGA. NMP-IL showed better physico-thermal stability, enhanced skin penetration, and enriched drug accumulation 2.6 times higher than that of IL [Cho][Ibu] in the target tissue. These results suggested that NMP cation based API-IL can be an effective biocompatible formulation for topical drug delivery by accumulating active drugs in the skin. (C) 2019 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molliq.2019.112166
• 作为产物：
  描述：

  N-甲基吡咯烷酮 在 盐酸 、 silver(l) oxide 作用下， 以 水 为溶剂， 反应 27.0h， 生成 water N-methyl-2-pyrrolidone
  参考文献：
  名称：

  Ionic liquids with N-methyl-2-pyrrolidonium cation as an enhancer for topical drug delivery: Synthesis, characterization, and skin-penetration evaluation

  摘要：

  The development of non-toxic ionic liquid-based active pharmaceutical ingredients (IL-APIs) for effective topical drug delivery is still challenging. The properties of IL-APIs can be boosted up by selecting potential biocompatible cations. Here, we introduced N-methyl-2-pyrrolidone (NMP) as a potent biocompatible counter ion to prepare ionic liquefied drugs for topical drug delivery. The cytotoxicity of NMP cation was investigated using mammalian cell lines (HepG2, NIH3T3 and L929 cells) and compared with conventional IL-forming cations. The synthesized NMP cation has lower toxicity than that of conventional IL-forming cations. The NMP cation showed at least 3.6, 15.2 and 58.9 times lower toxicity than that of conventional imidazolium, ammonium and phosphonium cations, respectively. The synthesized NMP-based ionic liquid (NMP-IL) was characterized using H-1 & C-13 NMR, FT-IR, DSC and TGA. NMP-IL showed better physico-thermal stability, enhanced skin penetration, and enriched drug accumulation 2.6 times higher than that of IL [Cho][Ibu] in the target tissue. These results suggested that NMP cation based API-IL can be an effective biocompatible formulation for topical drug delivery by accumulating active drugs in the skin. (C) 2019 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.molliq.2019.112166
• 作为试剂：
  描述：

  6-羟基-3,4-二氢-2(1H)-喹诺酮 、 sodium hydroxide 、 1-环己基-5-(4-氯丁基)-四氮唑 、 醋酸异丙酯 在 醋酸异丙酯 、 water N-methyl-2-pyrrolidone 、 水 作用下， 以 N-甲基吡咯烷酮 、 水 为溶剂， 反应 5.0h， 以to give 130.66 g (yield. 85.4%) of cilostazol的产率得到西洛他唑
  参考文献：
  名称：

  Process for the production of cilostazol

  摘要：

  一种从式II的6-羟基-3,4-二氢喹啉酮和式III的1-环己基-5-(4-卤丁基)-四唑制备式I的西洛他唑的方法，其中X是卤原子，例如Cl、Br和I，包括将化合物II、III、水溶性有机溶剂、水溶性碱和水结合起来。然后可以从反应混合物中分离出西洛他唑，并将其溶解在溶剂A中。将所得的西洛他唑溶液与溶剂B混合，沉淀出具有确定粒径范围的西洛他唑颗粒，如有需要则进行研磨，然后过滤和干燥产物。

  公开号：

  US20070105898A1

文献信息

• Method for retarding corrosion in petroleum processing operation using
  申请人：Exxon Research and Engineering Co.

  公开号：US04396492A1

  公开（公告）日：1983-08-02

  This invention is directed to a method of reducing the amount of corrosion resulting in a petroleum process operation wherein N-methyl pyrrolidone is utilized as one of the components by adding an effective corrosion inhibiting amount of an ester additive formed from a polycarboxylic acid and glycol or glycerol, preferably a dimer acid of linoleic acid and diethylene glycol.

  本发明涉及一种减少石油加工过程中腐蚀量的方法，其中N-甲基吡咯烷酮作为其中一种成分被使用，通过添加由多羧酸和乙二醇或甘油形成的酯添加剂的有效抑制腐蚀量的数量来实现，优选为亚油酸二聚体酸和二乙二醇。
• COMPOUNDS
  申请人：GORE Martin Paul

  公开号：US20080039444A1

  公开（公告）日：2008-02-14

  The present invention relates to compounds of formula (I), and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders, such as allergic rhinitis.

  本发明涉及式(I)化合物及其盐，其制备过程，含有它们的组合物以及它们在治疗各种疾病（如过敏性鼻炎）中的用途。
• 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists
  申请人：Gore Paul Martin

  公开号：US20090105225A1

  公开（公告）日：2009-04-23

  The present invention relates to compounds of formula (I), and salts thereof, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders, such as allergic rhinitis.

  本发明涉及公式(I)的化合物及其盐，其制备方法，含有它们的组合物以及它们在治疗各种疾病，如过敏性鼻炎中的应用。
• POLYCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20160264554A1

  公开（公告）日：2016-09-15

  The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7), cyclin-dependent kinase 12 (CDK12), or cyclin-dependent kinase 13 (CDK13)), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

  本发明提供了公式（I）的新型化合物，以及其药学上可接受的盐，溶剂合物，水合物，多晶形，共晶体，互变异构体，立体异构体，同位素标记衍生物，前药和其组合物。还提供了涉及本发明化合物或组合物的方法和试剂盒，用于治疗或预防主体中的增殖性疾病（例如，癌症（例如，白血病，淋巴瘤，黑色素瘤，多发性骨髓瘤，乳腺癌，尤因肉瘤，骨肉瘤，脑癌，神经母细胞瘤，肺癌），良性肿瘤，血管生成，炎症性疾病，自身炎症性疾病和自身免疫性疾病）。使用本发明化合物或组合物治疗患有增殖性疾病的主体可能抑制激酶的异常活性，例如细胞周期依赖性激酶（CDK）（例如，细胞周期依赖性激酶7（CDK7），细胞周期依赖性激酶12（CDK12）或细胞周期依赖性激酶13（CDK13）），从而在主体中诱导细胞凋亡和/或抑制转录。
• Ionic liquids with N-methyl-2-pyrrolidonium cation as an enhancer for topical drug delivery: Synthesis, characterization, and skin-penetration evaluation
  作者：Rahman Md Moshikur、Md Raihan Chowdhury、Rie Wakabayashi、Yoshiro Tahara、Noriho Kamiya、Muhammad Moniruzzaman、Masahiro Goto

  DOI：10.1016/j.molliq.2019.112166

  日期：2020.2

  The development of non-toxic ionic liquid-based active pharmaceutical ingredients (IL-APIs) for effective topical drug delivery is still challenging. The properties of IL-APIs can be boosted up by selecting potential biocompatible cations. Here, we introduced N-methyl-2-pyrrolidone (NMP) as a potent biocompatible counter ion to prepare ionic liquefied drugs for topical drug delivery. The cytotoxicity of NMP cation was investigated using mammalian cell lines (HepG2, NIH3T3 and L929 cells) and compared with conventional IL-forming cations. The synthesized NMP cation has lower toxicity than that of conventional IL-forming cations. The NMP cation showed at least 3.6, 15.2 and 58.9 times lower toxicity than that of conventional imidazolium, ammonium and phosphonium cations, respectively. The synthesized NMP-based ionic liquid (NMP-IL) was characterized using H-1 & C-13 NMR, FT-IR, DSC and TGA. NMP-IL showed better physico-thermal stability, enhanced skin penetration, and enriched drug accumulation 2.6 times higher than that of IL [Cho][Ibu] in the target tissue. These results suggested that NMP cation based API-IL can be an effective biocompatible formulation for topical drug delivery by accumulating active drugs in the skin. (C) 2019 Elsevier B.V. All rights reserved.